{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:40:25Z","timestamp":1787017225932,"version":"build-2736575974"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":153,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lupus ABC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>The Lupus Research Alliance formed the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) in 2023 as a public-private partnership with investigators, pharmaceutical companies, the Food and Drug Administration, National Institutes of Health, patient-focused non-profits and professional societies with the goals of developing initiatives to accelerate lupus drug development in a precompetitive setting, and ensuring that perspectives of people with lived experience of lupus are included into the drug development process. Patient-reported outcome (PRO) measures are a top area of focus for the Lupus ABC. To support future work in the area of PROs, a public meeting was held on 16\u201317 October 2024 with the objectives of (1) assessing the current state of PROs used in lupus clinical trials, (2) developing a roadmap to advance the use of PROs in lupus clinical trials and (3) identifying and setting priorities for efforts to be pursued by a Lupus ABC PRO Working Group. After a series of presentations, small groups addressed what PRO domains to measure, the questionnaire burden for trial participants, how PROs should be selected for trials and what efforts are needed to advance use of PROs in lupus clinical trials.<\/jats:p>\n                  <jats:p>Meeting participants concluded that although PROs are being collected in most lupus clinical trials, they may be underused as primary or secondary\/exploratory endpoints. A strong desire to change the focus in trials from disease activity and signs to include PROs, as a way of highlighting patients\u2019 voices, was noted. The group concluded that the specific steps needed are to identify PRO measures appropriate for the target populations of interest, incorporate PROs into endpoints for regulatory decision-making, ensure PRO data are publicly available and accessible to researchers and involve people living with lupus in selection of PRO domains, measures and trial design. For these actions, collaborations among industry, researchers, regulators, payors and patients are needed.<\/jats:p>","DOI":"10.1136\/lupus-2025-001876","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:22Z","timestamp":1764875422000},"page":"e001876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["New efforts to incorporate patient-reported outcomes into lupus clinical trials: report of the community meeting convened by the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), 16\u201317 October 2024"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-2519","authenticated-orcid":false,"given":"Patricia","family":"Katz","sequence":"first","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca D","family":"Askanase","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan","family":"Baruah","sequence":"additional","affiliation":[{"name":"Person living with lupus, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fisch","sequence":"additional","affiliation":[{"name":"Person living with lupus, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Garrard","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-2751","authenticated-orcid":false,"given":"Meenakshi","family":"Jolly","sequence":"additional","affiliation":[{"name":"Medicine, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Vargas Lupo","sequence":"additional","affiliation":[{"name":"Person living with lupus, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Mills","sequence":"additional","affiliation":[{"name":"Person living with lupus, Montclair, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elektra","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"AbbVie, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Park","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cooper","sequence":"additional","affiliation":[{"name":"Lupus Research Alliance, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Menezes","sequence":"additional","affiliation":[{"name":"Lupus Research Alliance, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora P","family":"Staeva","sequence":"additional","affiliation":[{"name":"Lupus Research Alliance, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Lupus Research Alliance, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Coney","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Cox","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Central Islip, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Eberspecher","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Hinsdale, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanelle","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Lerner","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Topanga, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda","family":"Logan","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Reyna","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Santa Cruz","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Kearney, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ung","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narae","family":"Yun","sequence":"additional","affiliation":[{"name":"Lupus Voices Council of Lupus ABC, Garrison, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2025120411101703000_12.2.e001876.1","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1136\/lupus-2019-000373","article-title":"Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review","volume":"7","author":"Strand","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025120411101703000_12.2.e001876.2","doi-asserted-by":"crossref","first-page":"152380","DOI":"10.1016\/j.semarthrit.2024.152380","article-title":"OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set","volume":"65","author":"Nielsen","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025120411101703000_12.2.e001876.3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/acr.25301","article-title":"Development of the American College of Rheumatology Patient\u2010Reported Outcome Quality Measures for Systemic Lupus Erythematosus","volume":"76","author":"Katz","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22881"},{"key":"2025120411101703000_12.2.e001876.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.12.005"},{"key":"2025120411101703000_12.2.e001876.6","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/acr.22349","article-title":"Development and Validation of the Lupus Impact Tracker: A Patient\u2010Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus","volume":"66","author":"Jolly","year":"2014","journal-title":"Arthritis Care & Research"},{"key":"2025120411101703000_12.2.e001876.7","unstructured":"Jolly M , Truman M , Flauto R , et al . Patient reported outcomes analyses from aurora 1 clinical trial: lupus impact tracker and lupuspro. arthritis rheum. Washington DC, 2024."},{"key":"2025120411101703000_12.2.e001876.8","unstructured":"PROMIS health measures. 2025. Available: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis"},{"key":"2025120411101703000_12.2.e001876.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161202"},{"key":"2025120411101703000_12.2.e001876.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23183"},{"key":"2025120411101703000_12.2.e001876.11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/acr.23797","article-title":"Psychometric Evaluation of the National Institutes of Health Patient\u2010Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort","volume":"71","author":"Katz","year":"2019","journal-title":"Arthritis Care & Research"},{"key":"2025120411101703000_12.2.e001876.12","first-page":"2102","article-title":"Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematous","volume":"30","author":"Moazzami","year":"2021","journal-title":"Lupus (Los Angel)"},{"key":"2025120411101703000_12.2.e001876.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"2025120411101703000_12.2.e001876.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004"},{"key":"2025120411101703000_12.2.e001876.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"2025120411101703000_12.2.e001876.16","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu332oa"},{"key":"2025120411101703000_12.2.e001876.17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41584-019-0190-1","article-title":"Measuring disease activity in SLE is an ongoing struggle","volume":"15","author":"Askanase","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025120411101703000_12.2.e001876.18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000875","article-title":"Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE","volume":"10","author":"Askanase","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025120411101703000_12.2.e001876.19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/acr.20503","article-title":"Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus","volume":"63","author":"Yazdany","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/acr.22268","article-title":"Longitudinal validation of the Brief Index of Lupus Damage","volume":"66","author":"Katz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/acr.20193","article-title":"Development and initial validation of a self-assessed lupus organ damage instrument","volume":"62","author":"Costenbader","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acr.24221","article-title":"Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage","volume":"72 Suppl 10","author":"Arora","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/acr.23794","article-title":"A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus","volume":"71","author":"Pisetsky","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025120411101703000_12.2.e001876.24","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S2665-9913(21)00387-8","article-title":"Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab","volume":"4","author":"Strand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025120411101703000_12.2.e001876.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202865"},{"key":"2025120411101703000_12.2.e001876.26","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research . Patient-focused drug development: collecting comprehensive and representative input. guidance for industry, food and drug administrative staff and other stakeholders (guidance 1). Silver Spring, MD; 2020."},{"key":"2025120411101703000_12.2.e001876.27","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research . Patient-focused drug development: identify what is important to patients. guidance for industry, food and drug administrative staff and other stakeholders (guidance 2). Silver Spring, MD; 2022."},{"key":"2025120411101703000_12.2.e001876.28","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research . Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. guidance for industry, food and drug administrative staff and other stakeholders (guidance 3). Silver Spring, MD; 2022."},{"key":"2025120411101703000_12.2.e001876.29","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research . Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. guidance for industry, food and drug administrative staff and other stakeholders (guidance 4). Silver Spring, MD; 2023."}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:25Z","timestamp":1764875425000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/lupus-2025-001876"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001876","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}